ProVision® Dr. Pierpaoli
ProVision® is an innovative formulation created to preserve eyesight. Food supplement with dry extract of Maqui and Blueberry, Zinc, Selenium, Vitamins E and A, Astaxanthin, Lutein and Melatonin.
ProVision® has been formulated to cover metabolic and oxidative needs of the eyes in general and of the retina in particular and has been developed based on a clinical trial.
Blueberry is beneficial for the well-being of eyesight; Maqui and Haematococcus pluvialis (Astaxanthin) for their antioxidant function; Zinc and Vitamin A contribute to maintaining normal eyesight; Selenium, Zinc, Maqui and Vitamin E protect cells from oxidative stress.
Average values per daily dose (1 tablet):
Zinc 8.74 mg (NRV 87.4%) dry extract titrated Blueberry fruits 15% anthocyanidins 50 mg – count of anthocyanidins 7.5 mg, Lutein 5 mg, Vitamin E 12 mg (NRV 100%), Astaxanthin 1 mg, Selenium 50 mcg (NRV 90.9%), Vitamin A 0.8 mg (100% NRV), Melatonin 1 mg.
General indications
• Beneficial for a healthy eyesight;
• Contributes to preserving eyesight;
• Contributes to protecting against oxidative stress;
• Helps to supplement the nutritional needs of the visual apparatus (retina, macula and crystalline);
• Helps to keep the visual apparatus in good conditions;
• Improves issues linked to visual fatigue.
• Moreover, ProVision® provides precious help to all people experiencing age-related macular degeneration.
The extensive use of computers, television, videogames and permanent artificial lights for hours every day, along with low humidity at home and in office, greatly stress and strain our eyes. In particular they “wear out” and “use up” the visual cells of the retina, which are “thirsty” for oxygen and minerals. Additionally, when they are stressed by an intense and variable light of changing wavelength (for example in discotheques), they tend to degenerate.
ProVision® and macular degeneration of the retina
Age-related macular degeneration of the retina (AMD) is a pathology that affects the macula (the centermost part of the retina). Today, it is considered to be the main cause of the loss of central vision (blindness) and, in industrialized countries, it is one of the leading causes of loss of visual acuity in subjects over 50.
The dry form is the more widespread (85% of patients) than the wet form (15%). Those affected present decreased vision in the central area of the visual field and/or a deformation of images. AMD progresses gradually and can lead to complete and irreversible loss of central vision (complete blindness is nonetheless rare).
The benefits of integration with ProVision® according the study
- Contributes to the control of eye pigmentation by regulating the light that reaches the photoreceptors
- Contributes to the elimination of toxic hydroxy-radicals
- Contributes to the protection of the retinal epithelium against oxidative damage
- Restores circadian rhythms
- Helps rebalance the neuroendocrine system
- Has excellent tolerance and easy oral administration
Dosage:
A tablet half an hour before going to bed, preferably between 10:00 pm - 12:00 am.
Instructions for use:
We recommend taking one tablet of Pierpaoli’s ProVision in the evening half an hour before going to sleep, and in any case preferably between 10 p.m. and midnight.
Warnings:
Do not exceed the recommended daily dose. Supplements are not intended as a substitute for a varied, balanced diet and healthy lifestyle. Keep out of reach of children under three years of age, do not take while pregnant, keep at a temperature below 25° C and protect from light.
Considerations of the safety of ProVision
In general
The use of the active ingredients in ProVision at recommended doses has been proven to be safe. Numerous scientific publications and studies confirm the safety and beneficial effects of the physiologically active substances contained in ProVision.
Interactions
For people that take medications before starting the integration with Pierpaoli’s ProVision, as more generally, with any other type of dietary supplement, we recommend consulting with your doctor. Although the pharmacokinetic/pharmacodynamic characteristics of the active physiological substances contained in ProVision are theoretically modulated by other active ingredients, currently, there are no known interactions that are of particular concern from a clinical viewpoint.
Special population groups
For precautionary purposes, we recommend that you always consult your doctor before taking ProVision if you suffer from: severe hepatic impairment and rheumatoid arthritis, given that, to date, there is not a great number of clinical observations in patients, it is necessary to validate the studies that prove the beneficial effects of ProVision in these categories of people. Given the lack of studies in this regard, taking ProVision should be avoided during pregnancy and subsequently while breastfeeding. In the absence of specific disorders, children and adolescents, unless a different specialised assessment proves otherwise, do not need to integrate ProVision.
Prolonged use
The use of the physiologically active ingredients contained in ProVision, at recommended doses, has been proven to be safe in the short and middle term (6-18 months). However, for precautionary purposes, we advise you to inform your doctor if you use it for prolonged periods.
References:
1. Hussein G et al. Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod. 2006 Mar;69(3):443-9. Review.
2. Stahl W. Macular carotenoids: lutein and zeaxanthin. Dev Ophthalmol. 2005;38:70-88. Review.
3. Dwyer JH, Paul-Labrador MJ, Fan J, Shircore AM, Merz CN, Dwyer KM. Progression of carotid intima-media thickness and plasma antioxidants: the Los Angeles Atherosclerosis Study. Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):313-9.
4. Ribaya-Mercado JD, Blumberg JB. Lutein and zeaxanthin and their potential roles in disease prevention. J Am Coll Nutr. 2004 Dec;23(6 Suppl):567S-587S. Review.
5. Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J . Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004 Apr;75(4):216-30.
6. PANG, S.F. & D.T. YEW. 1979. Pigment aggregation by melatonin in the retinal pigment epithelium and choroid of guinea pigs cavia porcellus. Experientia 35: 213 – 233.
7. Hartmann D, Thurmann PA, Spitzer V, Schalch W, Manner B, Cohn W. Plasma kinetics of zeaxanthin and 3'-dehydro-lutein after multiple oral doses of synthetic zeaxanthin. Am J Clin Nutr. 2004 Mar;79(3):410-7.
8. LIANG, F.Q., L. GREEN, C. WANG, et al. 2004. Melatonin protects human retinal pigment epithelial (RPE) cells against oxidative stress. Exp. Eye Res. 78: 1069 – 1075.
9. Stringham JM, Hammond BR Jr. Dietary lutein and zeaxanthin: possible effects on visual function. Nutr Rev. 2005 Feb;63(2):59-64. Review.
10. TOUITOU, Y., P. LE HOANG, B. CLAUSTRAT, et al. 1986. Decreased nocturnal plasma melatonin peak in patients with a functional alteration of the retina in relation with uveitis. 70: 170 – 174.
11. PIERPAOLI, W., A. DALL’ARA & E. PEDRINIS. 1991. The pineal control of aging: the effects of melatonin and pineal grafting on the survival of old mice. Ann. N.Y. Acad. Sci. 620: 291 – 313.
12. SCHER, J., E.WANKIEWICZ, G.M.BROWN, et al. 2003. AII amacrine cells express the MT1 melatonin receptor in human and macaque retina. Exp. Eye Res. 77: 375 – 382.